Matinas Other Current Liab from 2010 to 2025
| MTNB Stock | USD 1.27 0.07 5.83% |
Other Current Liabilities | First Reported 2012-12-31 | Previous Quarter 795 K | Current Value 564 K | Quarterly Volatility 974.6 K |
Check Matinas BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Matinas BioPharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Selling General Administrative of 7.6 M or Other Operating Expenses of 17.7 M, as well as many indicators such as Price To Sales Ratio of 36.64, Dividend Yield of 4.34 or PTB Ratio of 0.31. Matinas financial statements analysis is a perfect complement when working with Matinas BioPharma Valuation or Volatility modules.
Matinas | Other Current Liab | Build AI portfolio with Matinas Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Matinas BioPharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Matinas BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Matinas Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Matinas Biopharma Holdings Stock:Check out the analysis of Matinas BioPharma Correlation against competitors. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Matinas BioPharma. If investors know Matinas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Matinas BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Matinas BioPharma is measured differently than its book value, which is the value of Matinas that is recorded on the company's balance sheet. Investors also form their own opinion of Matinas BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Matinas BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Matinas BioPharma's market value can be influenced by many factors that don't directly affect Matinas BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Matinas BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Matinas BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Matinas BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.